Alnylam

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
Pharma Voice
Thu, 05/8/25 - 10:57 am
Alnylam
Rare Diseases
RNAi
R&D
Alnylam drug gets long-awaited FDA approval in deadly heart disease
BioPharma Dive
Thu, 03/20/25 - 10:05 pm
Alnylam
Amvuttra
Pfizer
Bridge Bio
FDA
ATTR-CM
Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space
BioSpace
Wed, 03/19/25 - 11:08 pm
Alnylam
ATTR-CM
Pfizer
Bridge Bio
vutrisiran
5 FDA decisions to watch in the first quarter of 2025
BioPharma Dive
Mon, 01/6/25 - 06:54 pm
FDA
Vertex Pharmaceuticals
non-opioid pain treatments
suzetrigine
GSK
vaccines
MenABCWY
meningitis
Alnylam
vutrisiran
transthyretin amyloid cardiomyopathy
Soleno
diazoxide choline
Prader Willi syndrome
Sanofi
hemophilia
fitusiran
Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race
First Word Pharma
Tue, 11/26/24 - 11:04 am
Alnylam
FDA
RNAi
vutrisiran
ATTR-CM
Alnylam boots Type 2 diabetes asset from haunted house
Fierce Biotech
Fri, 11/1/24 - 11:09 am
Alnylam
RNAi
type 2 diabetes
Alnylam agrees to drop patent lawsuit against Moderna over Covid-19 vaccine
Reuters
Sun, 10/6/24 - 10:50 pm
Alnylam
Moderna Therapeutics
legal
patents
vaccines
Alnylam’s vutrisiran aces ATTR cardiomyopathy readout
Pharmaphorum
Mon, 06/24/24 - 10:52 am
Alnylam
RNAi
vutrisiran
ATTR
cardiomyopathy
Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace
Fierce Pharma
Mon, 04/22/24 - 06:01 pm
Alnylam
Pfizer
Amvuttra
ATTR-CM
tafamidis
Alnylam changes to heart drug trial spark doubts, sinking shares
BioPharma Dive
Thu, 02/15/24 - 07:13 pm
Alnylam
clinical trials
vutrisiran
ATTR
Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection
BioSpace
Thu, 10/26/23 - 10:39 am
Alnylam
Patisiran
clinical trials
FDA
ATTR with cardiomyopathy
Interest in RNA Editing Accelerates as Therapies Approach the Clinic
BioSpace
Wed, 10/18/23 - 11:37 am
RNA editing
Alnylam
Shape Therapeutics
Eli Lilly
ProQR Therapeutics
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Pharma Voice
Thu, 10/12/23 - 05:32 pm
Alnylam
Pharma CEOs
Yvonne Greenstreet
FDA
Onpattro
FDA denies expanded approval for Alnylam RNA drug
BioPharma Dive
Mon, 10/9/23 - 10:15 am
Alnylam
FDA
RNA
Patisiran
ATTR amyloidosis
With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam
Fierce Pharma
Mon, 10/2/23 - 06:36 pm
Novo Nordisk
Rivfloza
FDA
primary hyperoxaluria type 1
RNAi
Alnylam
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Fierce Pharma
Mon, 09/18/23 - 08:01 pm
Pfizer
BridgeBio
Alnylam
FDA
clinical trials
ATTR-CM
physicians
tafamidis
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Fierce Pharma
Thu, 09/14/23 - 09:59 am
Alnylam
FDA
Onpattro
ATTR-CM
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
BioSpace
Tue, 09/12/23 - 07:06 pm
Alnylam
FDA
ATTR-CM
Onpattro
Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
BioSpace
Thu, 09/7/23 - 10:49 pm
Alnylam
Roche
PAH
zilebesiran
clinical trials

Pages